United Therapeutics (BSP:U2TH34) Beta: N/A (As of Jul. 07, 2026)


BSP:U2TH34 United Therapeutics Corp BSP:U2TH34
65 GF Score
Price R$137.50
GF Value R$97.21
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is United Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-07), United Therapeutics's Beta is Not available.

United Therapeutics  (BSP:U2TH34) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

United Therapeutics Beta Related Terms

United Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Beta Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSP:U2TH34
65GF Score
United Therapeutics Corp BSP:U2TH34
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is United Therapeutics (BSP:U2TH34) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of R$137.50 is trading 41.4% above its estimated GF Value™ of R$97.21. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for BSP:U2TH34:

  • Beta: N/A
  • GF Value™: R$97.21 vs. price of R$137.50 (41.4% above fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the BSP:U2TH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTHR:USAUTH:Germany
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
65GF Score

Get the complete analysis for BSP:U2TH34

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$137.50
Price
R$97.21
GF Value